Fetal growth restriction (FGR) is a serious pregnancy complication, resulting in significant perinatal morbidity and mortality. Increased vascular resistance in the fetoplacental circulation is a hallmark of FGR and is associated with enhanced vasoconstriction of the resistance arteries in the placenta, the chorionic plate arteries (CPAs). Although the cause is unknown, FGR is associated with excess exposure to glucocorticoids (GCs), key mediators of vascular resistance in the systemic circulation. We hypothesized that GCs alter CPA reactivity, thereby contributing to the altered blood flow dynamics seen in FGR. We aimed to examine the acute and chronic effects of GCs on CPA reactivity and the operational mechanisms. Glucocorticoid receptors were highly expressed by CPA. 11␤-Hydroxysteroid isoenzyme type 2 was detected within the endothelium, whereas 11␤-hydroxysteroid isoenzyme type 1 was absent. Acute GC treatment significantly attenuated U46619-induced constriction. This effect was reversed by cotreatment with mifepristone or an endothelial NOS inhibitor. In contrast, chronic GC treatment potentiated U46619 constriction in a dose-dependent manner, which was partially abolished by mifepristone cotreatment. Similar effects were observed using a novel nonsteroidal glucocorticoid receptor-specific agonist. Chronic treatment with GCs altered the expression of several vasoactive factors, including thromboxane and bradykinin receptors, prokineticin-1, cyclooxygenase-2, and endothelial NOS. In summary, acute and chronic GC treatment exerts contrasting effects on CPA vasoreactivity. These opposing effects are consistent with temporal actions in other vascular beds and reflect activation of distinct nongenomic and genomic pathways. Chronic exposure to elevated GCs may contribute to the raised vascular resistance observed in the fetoplacental circulation in FGR. (Endocrinology 154: 876 -887, 2013) 
F
etal growth restriction (FGR) is the pathological inhibition of fetal growth and the consequent failure of the fetus to attain its growth potential. It affects between 4%-8% of all pregnancies and is strongly associated with stillbirth and neonatal morbidity (1, 2) . However, effects of FGR are not limited to very early life, with epidemiological and animal studies demonstrating a robust link between low birth weight and susceptibility to chronic diseases in adulthood (3, 4) . In pregnancies complicated by FGR, Doppler waveform analyses of umbilical arteries identify an increase in resistance to blood flow in the fetoplacental circulation (5-7), indicating abnormal delivery of oxygen and nutrients to the fetus.
The mechanisms underlying this increased vascular resistance are unknown. Placental blood vessels are not in-nervated and therefore fetoplacental blood flow is regulated primarily by local environmental and humoral factors (8) . Umbilical arteries branch on the fetal surface of the placenta to form chorionic plate arteries (CPAs); these arteries exhibit the characteristics of resistance arteries (Ͻ300 m internal diameter) and are therefore likely to contribute significantly to modulating vascular tone in the fetoplacental circulation (9) . CPA reactivity has previously been shown to be altered in placentas from pregnancies complicated by FGR (10) , with increased constriction to the thromboxane-mimetic, U46619, and increased relaxation to the nitric oxide (NO) donor, sodium nitroprusside (SNP), suggesting aberrant control of vascular tone contributes towards the increased vascular resistance.
Glucocorticoids (GCs) have well-documented actions in the regulation of systemic vascular reactivity, both via genomic and nongenomic pathways (11) . Glucocorticoid receptors (GRs) are expressed in both smooth muscle and endothelial cells (12, 13) together with both 11␤-hydroxysteroid (11␤-HSD) isoforms, indicating a possible role for prereceptor GC metabolism (14) . The placenta and developing fetus are partially protected from maternal cortisol in pregnancy by the activity of 11␤-HSD2 in the placental syncytiotrophoblast, in which this enzyme metabolizes cortisol to its inactive metabolite cortisone (15) . However, in pregnancies complicated by FGR, 11␤-HSD2 expression and activity is reduced (16) . It has been speculated that the ensuing elevated exposure of the fetoplacental unit to cortisol contributes to the pathogenesis of FGR, a hypothesis supported by reduced birth weight in animal models after maternal GC administration (17) (18) (19) or gene ablation of 11␤-HSD2 (20) . Given the established roles for GCs in modulating vascular tone, GC excess may contribute to the increased CPA vasoconstriction and raised vascular resistance observed in placentas from pregnancies complicated by FGR.
The in vitro effects of acute exposure to GCs on the fetoplacental circulation have been investigated previously. In perfused placental cotyledons, dexamethasone infusion significantly reduced basal arterial pressure and induced vasodilatation following a submaximal KCl-induced vasoconstriction (21) . Hydrocortisone, dexamethasone, and betamethasone also had an acute vasodilatory effect on rings of human umbilical arteries, preconstricted with 5-hydroxytryptamine (22) . These vasodilatory effects are consistent with previous observations of acute actions of GCs in systemic blood vessels. However, the longer-term actions of GCs on placental arteries have not been examined.
We hypothesized that GCs alter CPA reactivity, thereby contributing to the altered blood flow dynamics seen in pregnancies complicated by FGR. The aims of this study were to determine the following: 1) whether CPAs express the proteins involved in the cellular actions of GCs and 2) the acute and chronic actions of GCs on the vascular reactivity of CPAs.
Materials and Methods
All drugs and chemicals were obtained from Sigma-Aldrich (Dorset, UK) unless stated otherwise.
Placental collection
The Central Manchester and North West Regional Ethics Committees gave approval for this work at St Mary's Hospital, Manchester (08/H1010/55). Written informed consent was obtained for all samples used. Term placentas were obtained after vaginal delivery or elective cesarean section from women who had otherwise uncomplicated pregnancies. All deliveries were between 37 and 42 weeks of gestation and had an individualized birth weight centile 10th or greater and 90th or less centile. Women with preexisting medical or obstetric disorders were excluded.
Localization of GR and 11␤-HSD isoforms in CPA
Chorionic plate biopsies were fixed in 10% neutral-buffered formalin at 4°C, prior to routine wax embedding. Immunohistochemical staining for vascular markers ␣-smooth muscle actin [␣-SMA; vascular smooth muscle cells (VSMCs)] and CD31 (endothelial cells) was performed on 5-m tissue sections to identify CPA as previously described (23) using monoclonal antibodies: anti-CD31 and anti-␣SMA (Dako, Glostrup, Denmark) applied at 1.33 and 5 g/mL, respectively, followed by standard immune-peroxidase detection with diaminobenzidine chromogen and hematoxylin counterstaining. A similar protocol was utilized to localize GR, 11␤-HSD1, and 11␤-HSD2 within CPA. For GR, a mouse monoclonal antibody (Novocastra, Leica Biosystems, Milton Keynes, United Kingdom) was applied at 2.4 g/mL. For 11␤-HSD1, a rabbit polyclonal antibody raised against human 11␤-HSD1 (Cayman Europe, Tallinn, Estonia) was applied at 2 g/mL. For 11␤-HSD2, a sheep polyclonal antihuman 11␤-HSD2 (kind gift from M. Kilby and P. Stewart, University of Birmingham, Birmingham, UK) antibody was applied at a 9 g/mL. In all cases, a serial section was incubated with nonimmunized IgG from the appropriate species at a matching concentration to the primary antibody as a negative control.
Immunohistochemically stained chorionic plate sections were imaged using an Olympus BX41 microscope with QI-cam video capture (Olympus, Southend-on-Sea, United Kingdom), and ImagePro Plus 7.0 Software (Media Cybernetics, Marlow, United Kingdom). CPAs were identified by ␣-SMA and CD31 immunostaining. The serial sections were examined for localization of GR, 11␤HSD1, and 11␤HSD2. Under a stereomicroscope, small CPAs were identified and dissected. Four arterial segments, 2-3 mm in length, were mounted on a Danish Myotechnologies M610 wire myograph (Aarhus, Denmark). Each bath contained 6 mL of PSS, warmed to 37°C, and gassed with 5% O 2 /5% CO 2 /N 2 (BOC Special Gases, Worsely, United Kingdom). CPAs were normalized to 0.9 of L 5.1 kPa as described previously (9) . After normalization, vessels were equilibrated (20 minutes) prior to the commencement of the experiment. Vessel viability was assessed using 120 mM KCl PSS (KPSS), and vessels were excluded if they did not constrict more than 1.995 kPa.
Effect of acute GC exposure on vasodilatation
CPAs were preconstricted with U46619 (10 Ϫ7 M; approximate EC 80 ) and relaxation measured in response to incremental doses of hydrocortisone (10 Ϫ10 to 10 Ϫ5 M) or dexamethasone (10 Ϫ10 to 10 Ϫ5 M at 2 minute intervals). Vessel segments were also incubated with carbenoxolone (an 11␤-HSD2 inhibitor, 10 Ϫ7 M) for 15 minutes prior to preconstriction with U46619 (10 Ϫ7 M). Vessel relaxation was then measured in response to incremental doses of hydrocortisone (10 Ϫ10 to 10 Ϫ5 M at 2 minute intervals). Time controls were exposed to an equivalent volume of diluent and run in parallel.
Effect of acute GC exposure on basal tone and subsequent vasoconstriction
CPAs were incubated with hydrocortisone (10 Ϫ6 M) in the presence and absence of carbenoxolone (10 Ϫ7 M) or dexamethasone (10 Ϫ6 M) for 60 minutes. Basal tone was measured at time 0 and 60 minutes after the treatment. Vessels were then exposed to increasing doses of U46619 (10 Ϫ10 to 2 ϫ 10 Ϫ6 M). Time controls were exposed to an equivalent volume of diluent and performed in parallel. To investigate potential effectors of GC effects, a subset of CPA was treated with dexamethasone (10 Ϫ6 M) in the presence and absence of either mifepristone (a GR antagonist, 10 Ϫ5 M) or N()-nitro-L-arginine [LNNA; nitric oxide synthase (NOS) inhibitor, 10
Ϫ5 M] for 60 minutes. Basal tone was assessed before and after the treatment, and the effect of increasing doses of U46619 was assessed as above.
Chronic effect of GCs on chorionic plate vascular reactivity

Determination of optimal conditions for CPA culture
Isometric wire myography has been widely used to study the short-(few hours) but not the long-term actions of a variety of pharmacological agents on isolated CPAs. A culture system was therefore developed to maintain CPA viability and function for at least 24 hours, thereby allowing for changes in gene expression and protein synthesis. Multiple segments of CPAs, 2-3 mm in length, were prepared and cultured for 24 hours in DMEM or CMRL medium (medium developed at the Connaugh Medical Research Laboratories) supplemented with 10% fetal calf serum (BioSera, Ringmer, United Kingdom); 1% penicillin, streptomycin, and glutamine, at either 5% or 20% O 2 at 37°C. After culture, vessels were mounted on the wire myograph as described above. Constriction in response to 120 mM KPSS and U46619 (10 Ϫ10 to 2 ϫ 10 Ϫ6 M) was measured, followed by assessment of relaxation to SNP [10 Ϫ11 to 10 Ϫ4 M; preconstricted with U46619 (EC 80 )].
A further set of cultured vessels was fixed in 10% neutral buffered formalin, wax embedded, and immunostained for vascular markers as described above. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining was also performed to assess vascular cell viability using the in-situ cell death detection kit with peroxidise detection (Roche Diagnostics, Mannheim, Germany) in accordance with the manufacturer's instructions with minor modifications. The reaction mix comprised terminal deoxynucleotidyl transferase (prediluted 1:10 with TUNEL dilution buffer), and fluorescein isothiocyanate-labeled deoxyuridine 5-triphosphate (prediluted 1:2), at a ratio of 1:10. For negative controls, fluorescein isothiocyanate-deoxyuridine 5-triphosphate was applied alone.
Effect of long-term GC exposure on vasoconstriction and vasodilation
Segments of CPAs were cultured for 24 hours as above with dexamethasone (10 Ϫ8 to 10 Ϫ6 M) or hydrocortisone (10 Ϫ8 to 10 Ϫ6 M) in the presence and absence of carbenoxolone (10 Ϫ7 M). Control CPAs were cultured with vehicle alone (0.01% ethanol). Subsets of CPAs were cotreated with dexamethasone and mifepristone (10 Ϫ5 M) or a nonsteroidal GR-specific agonist (GSK47869A, 10 Ϫ6 M, kind gift from GlaxoSmithKline UK Ltd, Middlesex, United Kingdom) to verify GC action through the GR. Constriction (120 mM KPSS; 10 Ϫ10 to 2 ϫ 10 Ϫ6 M U46619) and relaxation (SNP, 10 Ϫ11 to 10 Ϫ4 M) were measured as noted above. Time controls were exposed to an equivalent volume of diluent and performed in parallel.
Effect of long-term GC-treatment on CPA gene expression
A further set of CPAs were cultured in DMEM-based media at 5% O 2 (n ϭ 10 placentas) with dexamethasone (10 Ϫ6 M), hydrocortisone (10 Ϫ6 M), or vehicle control. RNA was extracted from CPAs using the RNeasy fibrous tissue minikit (Qiagen, Crawley, United Kingdom) according to the manufacturer's guide, including on-column deoxyribonuclease treatment. The RNA purity and concentration were determined by UV spectrophotometry (Eppendorf, Cambridge, UK) and Quant-iT RiboGreen RNA assay kit (Life Technologies, Paisley, United Kingdom). RNA samples (25 ng) were reverse transcribed using the AffinityScript multiple temperature cDNA synthesis kit (Agilent Technologies, Wokingham, United Kingdom) using random hexameric primers. The expression of genes with established vascular reactivity actions (Table 1) were assessed by real-time quantitative PCR, alongside the housekeeping gene TATA-box binding protein (TBP). cDNA samples were amplified using the Brilliant II SYBR Green QPCR master mix kit (Agilent Technologies), containing 0.25 M forward and reverse primers. PCRs were run in a MX3005P real-time PCR machine (Agilent Technologies) using the following protocol: 95°C for 10 minutes, 40 cycles of 95°C for 30 seconds, 60°C for 60 seconds, and 72°C for 60 seconds, with fluorescence monitoring every cycle. A dissociation peak was performed to ensure a single product and amplicon size was confirmed by gel electrophoresis (2% agarose gel). Gene expression levels in GC-treated CPAs relative to controls were calculated from the cycle threshold values (2-⌬⌬CT).
Statistical analysis
Vessel tension production was expressed as a percentage of the initial maximal constriction to KPSS or as active wall tension (mN per millimeter) and transformed to active effective pressure (kilopascals) to standardize for variations in vessel diameter. For statistical analysis of U46619 and SNP dose-response curves, data were log transformed and compared by repeated-measures, 2-way ANOVA with Bonferroni post hoc tests using GraphPad Prism (GraphPad, San Diego, California). P values, F values, and degrees of freedom are quoted for all significant effects. The EC 50 or EC 80 of U46619 was calculated using the curve-fitting function. Sensitivity and maximal effect data were compared using the Mann-Whitney U test or Kruskall-Wallis with Dunn's post hoc test. PCR data were analyzed using Wilcoxon signed rank test. All data are expressed as mean Ϯ SEM or median Ϯ interquartile range for n placentas; 3 or 4 vessels were studied and averaged per placenta. A value of P Ͻ .05 was indicative of statistical significance.
Results
Localization of GR and 11␤-HSD1 and -2 in CPA
Immunoreactivity for CD31 and ␣-SMA was used to identify the endothelial and vascular smooth muscle layers in the walls of CPA (Figure 1, A and B) . Both the endothelium and vascular smooth muscle showed strong nuclear immunoreactivity for GR (Figure 1, D and E) . Villous placenta was included as a positive control (24) and showed strong nuclear immunoreactivity in the stromal compartment; no staining was detected in the negative control ( Figure 1F 
Acute effects of GCs on CPA vascular reactivity
Effect of acute GC exposure on vasorelaxation
Dexamethasone ( reach statistical significance (P ϭ .07, F ϭ 3.60, Df ϭ 1, 2 way ANOVA; Figure 2B ). Cotreatment with dexamethasone and LNNA inhibited the attenuation in U46619-induced constriction (P Ͻ .05, F ϭ 5.59, Df ϭ 1, compared with dexamethasone treatment, 2 way ANOVA; Figure 2C ).
Chronic effect of GCs on CPA vascular reactivity
Determination of optimal conditions for CPA culture
Preliminary experiments demonstrated a significant reduction in KPSS-and U46619-induced contraction of 
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CPAs cultured for 24 hours in DMEM-or CMRL-based media using 20% O 2 when compared with fresh CPAs (data not shown). CPAs cultured in DMEM for 24 hours at 5% O 2 produced similar contractile function compared with fresh vessels from the same placenta; in CMRL, vessel reactivity was significantly attenuated (n ϭ 6, P Ͻ .05, Mann-Whitney U test; Figure 3 M and above. Sensitivity to U46619 (EC 50 ) was not significantly altered (P Ͻ .05, Kruskal-Wallis, Figure 4D ), but dexamethasone (10 Ϫ6 M) induced a significantly elevated maximal constriction to U46619 (P Ͻ .05, Kruskall Wallis with Dunn's post hoc test, Figure 4E ). Hydrocortisone incubation (24 hours; 10 Ϫ6 M) significantly increased U46619-induced vasoconstriction (n ϭ 12, P Ͻ .0001, F ϭ 18.15, Df ϭ 1; 2 way ANOVA; Figure  5A ). Sensitivity to U46619 (EC 50 ) was significantly increased (P Ͻ .01, Mann Whitney, Figure 5B ), without significant alterations in maximum constriction (not shown). The effect of hydrocortisone was dose dependent (10 Ϫ7 and 10 Ϫ8 M had no effect on U46619 constriction; n ϭ 6, data not shown) and was abolished in the presence of carbenoxolone (P Ͼ .05, 2 way ANOVA; Figure 5C ). Culture of CPAs with carbenoxolone alone had no effect on U46619-induced constriction ( Figure 5D ). To determine the mechanism underlying GC-potentiated vasoconstriction, CPAs were treated with mifepristone (GR antagonist, 24 hours, 10 Ϫ5 M), in the presence and absence of dexamethasone (10 Ϫ6 M), together with untreated time controls ( Figure 5E ). The previously observed potentiation of vasoconstriction was observed with dexamethasone treatment (10 Ϫ6 M; P ϭ .0014, F ϭ 10.81, Df ϭ 1 compared with control CPA, 2 way ANOVA). Cotreatment with dexamethasone and mifepristone partially abolished this effect, although this did not reach statistical significance (P ϭ .14, F ϭ 2.22, Df ϭ 1, compared with dexamethasone alone, 2 way ANOVA). Mifepristone treatment alone had a marginal, but not significant, stimulatory effect on vasoconstriction compared with control vessels, suggesting a slight agonist response to mifepristone in this model (P ϭ .09, F ϭ 2.86, Df ϭ 1).
Further confirmation of an involvement of GR in the potentiation of U46619-induced vasoconstriction was obtained by treating CPAs with a nonsteroidal GR agonist (GSK47869A at 10 Ϫ6 M; 24 hours). In the continued presence of GSK47869A, U46619-induced vasoconstriction was significantly enhanced, confirming that the effect is mediated through the GR (P ϭ .012, F ϭ 6.54, Df ϭ 1, 2 way ANOVA; Figure 5F ). Dexamethasone (10 Ϫ8 to 10 Ϫ6 M) did not significantly modify SNP-induced relaxation of CPAs preconstricted with an EC 80 dose of U46619 (P Ͼ .05, 2 way ANOVA; data not shown).
Effect of GCs on CPA gene expression
To investigate the potential molecular mechanisms involved in GC-enhanced vasoconstriction, expression of 6 genes [thromboxane receptor (TBX-R), prokineticin-1 (PROK1), angiotensin II receptor type 1 (AGTR1), bradykinin receptor, cyclooxygenase (COX)-2, and endothelial nitric oxide synthase (eNOS), known to regulate CPA tone] were amplified using real-time PCR in CPAs cultured with dexamethasone or hydrocortisone (10 Ϫ6 M), compared with vehicle control. Exponential amplification curves were obtained, with no amplification in the negative control. TBP (housekeeping gene) mRNA was not significantly altered by GCs; thus, all data are normalized for TBP expression levels. TBX-R mRNA expression was significantly up-regulated by dexamethasone (P Ͻ .001) and hydrocortisone (P Ͻ .01), whereas PROK1 was upregulated by hydrocortisone only (P Ͻ .05) and AGTR1 was unchanged by GC treatment (Figure 6 ). Bradykinin receptor mRNA expression was significantly reduced by dexamethasone and hydrocortisone (P Ͻ .001), as was COX-2 (P Ͻ .01). Unexpectedly, eNOS mRNA expression was significantly elevated by dexamethasone or hydrocortisone (P Ͻ .05 for both). 
Discussion
The aim of this study was to determine whether GCs affect CPA vascular reactivity and hence have the potential to contribute to the aberrant vascular function observed in pregnancies complicated by FGR. Strong nuclear immunoreactivity for GR was identified in CPA endothelial and vascular smooth muscle cells, supporting that GCs may influence fetoplacental vascular tone via actions on both cell types. Acute exposure to dexamethasone induced a small, but significant, reduction in vasoconstriction, whereas chronic exposure to dexamethasone or hydrocortisone exerted a dose-dependent augmentation of vasoconstriction. These 2 opposing effects are consistent with temporal actions in other vascular beds and reflect downstream activation of distinct nongenomic and genomic pathways. Acute dexamethasone exposure attenuated U46619-induced vasoconstriction of CPAs by approximately 15%. A reduction of this magnitude would be expected to significantly affect spatial blood flow within the placenta due to the key role of CPA as placental resistance arteries (8) . However, in contrast to previous observations using the intact placental lobule perfusion technique (21), dexamethasone did not induce dilatation in unstimulated or preconstricted CPAs. This is likely due to differences in the methodologies used; placental perfusion models incorporate a number of blood vessel subtypes and nonvascular cell types in the villous tissue, which may respond to experimental conditions by release of vasoactive factors (eg, thromboxane, prostaglandins) (25) . The current study delineates the contribution of altered CPA tone to the overall effect and suggests that acute GCs induce additional vasorelaxatory effects in the distal portions of the vascular tree.
The importance of GR to the acute responses to dexamethasone is underlined by the abolition of the effect with mifepristone. Furthermore, the inhibition/attenuation of the dexamethasone effect by the eNOS inhibitor LNNA suggests that short-term dexamethasone treatment blunted CPA vasoconstriction through a local up-regulation of NO synthesis stimulated by nongenomic GR activation. This mechanism is consistent with previous reports of the nongenomic actions of GCs in human saphenous vein endothelial cells (26) .
The observations after acute exposure of CPAs to GCs may explain the acute improvement in umbilical artery Doppler waveforms after corticosteroid administration in pregnancies complicated by severe FGR (27, 28) . However, the chronic effects of GCs on the fetoplacental vasculature are clinically more relevant in deciphering the 
pathophysiological mechanisms in FGR. Previous myography studies have focused on short-term actions of a variety of pharmacological agents (9, 29) . A culture system was therefore successfully developed to maintain CPA viability and permit assessment of the longer-term effects of GCs on CPA vascular function. Chronic dexamethasone exposure potentiated U46619-induced CPA constriction in a dose-dependent manner; hydrocortisone exposure produced similar effects but only at the highest concentration used. This potentiation of vasoconstriction mimics the FGR placental phenotype in CPAs (10) and provides a potential mechanistic link between placental exposure to elevated GCs and the increased vascular resistance in FGR placentas. Initial studies to elucidate the mechanisms involved used the GR antagonist mifepristone. Cotreatment with mifepristone partially abolished the dexamethasone-induced potentiation of vasoconstriction, suggesting the chronic effects of glucocorticoids are mediated via GR. To add support to this hypothesis, we made use of a new series of highly GR-specific agonists, which lack any detectable mineralocorticoid receptor binding activity. One of these, GSK47869A, produced a near identical effect to both dexamethasone and hydrocortisone, thereby strongly supporting the conclusion that this response is mediated through GR.
Mifepristone treatment alone produced a slight potentiation of vasoconstriction to dexamethasone. Although this was not statistically significant, it may reflect a GR agonist effect, as previously described in cells with high receptor density (30, 31) . Alternatively, it may reflect blockade of progesterone receptors by mifepristone; PRs are abundantly expressed by CPA, and progesterone exerts potent vasodilatory effects on these vessels (32, 33) . Thus, the antagonism of progesterone present in the culture medium (supplemented with fetal calf serum) may contribute to the small increase in CPA constriction induced by mifepristone. GR is expressed in both endothelial and vascular smooth muscle cells in other human blood vessels. GCs are thought to modulate vascular tone through actions in both cell types: GCs inhibit vasodilator release (NO, prostacyclin) (34, 35) from endothelial cells and increase vasoconstrictive effects of catecholamines and angiotensin II by up-regulating ␣1B-adrenergic and AGTR1, respectively, in vascular smooth muscle cells (36, 37) . Our PCR analyses provided evidence that dexamethasone and hydrocortisone alter the balance of vasoconstrictor and vasodilatory action in favor of constriction by enhancing CPA . Effects of chronic exposure to glucocorticoid agonists and antagonists on CPA vasoconstriction. A, Constriction to U46619 was potentiated after culture with hydrocortisone (HC; 10 Ϫ6 M) compared with diluent control. *** P Ͻ .001 (2 way ANOVA). B, Hydrocortisone increased sensitivity to U46619, demonstrated by a significantly lower EC 50 . ** P Ͻ .01, MannWhitney test (data shown as box and whisker plots). Cotreatment with HC and carbenoxolone (CBX; 10 Ϫ7 M) abolished the potentiating effect of HC on CPA constriction (C), whereas carbenoxolone alone had no significant effect on U46619-induced constriction (D). Data in A, C, and D are mean Ϯ SEM (n ϭ 12). E, The previously observed potentiation of vasoconstriction induced by Dex (** P Ͻ .01, 2 way ANOVA; † † P Ͻ .01, † P Ͻ .05, Bonferroni post hoc test) was abolished by cotreatment with mifepristone (*** P Ͻ .001, compared with Dex treatment, 2 way ANOVA). F, Exposure to nonsteroidal glucocorticoid receptor agonist GSK47869A significantly potentiated constriction to U46619 compared with control (** P Ͻ .01). Data in E and F are mean Ϯ SEM (n ϭ 7-10).
TBX-R expression and decreasing bradykinin receptor and prostaglandin production via reduced COX-2 expression. Moreover, PROK1, a potent stimulator of smooth muscle constriction (38) , is also enhanced, whereas AGRT1 was unaffected. These data suggest GCs induce highly selective effects on vasoconstrictive pathways in CPAs. TBX-R up-regulation is particularly pertinent to the current study because GCs potentiated constriction in response to U46619, a thromboxane-mimetic, and the TBX-R contains a GRE in its promoter region (39) . Thromboxane A 2 has been implicated in the pathogenesis of FGR because transgenic mice overexpressing TBX-R deliver growth-restricted pups (40) . It is unknown whether there is an increase in TBX-R expression in CPAs from human pregnancies complicated by FGR.
In the current study, dexamethasone did not significantly alter SNP-induced vasorelaxation of CPAs, despite an increase in mRNA expression of eNOS after GC exposure. However, SNP exposure tests the ability of vascular smooth muscle to respond to available NO rather than assessing NO bioavailability. Previous studies have shown that NO bioavailability and eNOS expression is reduced by GC exposure (35, 41) . The reasons for the discrepancy between our findings and previously published data are unclear, but increased eNOS expression in the current study may represent a compensatory response to the culture conditions used. Unlike CPAs from normal pregnancies, vessels from FGR pregnancies maintain relaxation in response to high concentrations of SNP (10) , and a similar response was also observed in cultured CPAs in the current study. This effect can also be reproduced by hypoxia (42) . The comparable effect on vasodilatation in cultured vessels with the visible loss of the endothelium and in experimentally induced hypoxia is consistent with proposed endothelial cell dysfunction in FGR pregnancies (43) .
The distribution of the 11␤-HSD isoenzymes within CPAs has not been examined previously. Although both isoforms are detectable in VSMCs and endothelial cells in vitro (44), 11␤HSD-1 has been shown to be specifically expressed by endothelial cells in vitro, with 11␤-HSD1 localized to VSMCs (14) . Here we demonstrated 11␤-HSD2 immunoreactivity in CPA endothelial cells, albeit at a low level, whereas 11␤-HSD1 was undetectable. This latter finding contrasts with a previous study describing 11␤-HSD1 immunoreactivity within the umbilical cord and villous tree vascular endothelium (45) . This may be attributed to differences in antibody efficacy; however, the detection of strong and selective immunostaining in decidual cells from term fetal membranes suggests a high antibody specificity in the current study. CPA expression of 11␤-HSD2 suggests a further level of protection for the fetoplacental vasculature against maternal cortisol.
In both acute and chronic experiments, hydrocortisone was less effective than dexamethasone. This may be due to metabolism by 11␤-HSD2; however, 11␤-HSD2 inhibition with carbenoxolone failed to increase the magnitude of the vasoconstrictor response to hydrocortisone. This is A-C, TBX-R and PROK1 were significantly up-regulated by GCs, whereas AGTR1 was unaffected. D-F, Bradykinin receptor and COX-2 were significantly downregulated by glucocorticoids, whereas eNOS was significantly up-regulated by HC and DEX. * P Ͻ .05, ** P Ͻ .01, *** P Ͻ .001, compared with control CPA (Wilcoxon signed rank test).
Endocrinology, February 2013, 154(2):876 -887 endo.endojournals.orgunlikely to be due to a dosage effect because lower carbenoxolone concentrations have previously been demonstrated to reduce 11␤-HSD2 activity (46, 47) . The differences in the magnitude of response are therefore more likely to be due to the relatively higher potency of dexamethasone than hydrocortisone (48) . Interestingly, carbenoxolone appeared to abolish the hydrocortisone-induced increase in U46619 vasoconstriction; this is likely to be an 11␤-HSD2-independent effect of carbenoxolone on vascular function, as a gap junction inhibitor (49, 50) , or by increasing apoptosis (20) . In summary, this study has demonstrated contrasting acute and chronic actions of GCs on CPAs, consistent with observations from other vascular beds. Blunted constriction to U46619 after acute GC exposure may explain the transient improvement in fetoplacental blood flow after antenatal GC treatment, whereas the enhanced vasoconstriction after longer-term exposure mimics the altered reactivity of CPA from pregnancies complicated by FGR. The exact mechanism behind this potentiation in constriction to thromboxane has not been fully elucidated; however, altered expression of vasoactive factors suggests dysregulation of autocrine/paracrine mediators of CPA tone in favor of vasoconstriction. Taken together, these findings support the hypothesis that exposure to elevated GCs may contribute to the pathogenesis of raised vascular resistance in the fetoplacental circulation in FGR.
